OTC$PTN
Palatin Technologies Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Announced financial results for its fiscal second quarter ended December 31, 2022.
Palatin Technologies reported an increase in Vyleesi's net product sales by 18% and prescriptions dispensed by 12% over the prior quarter. Net product revenue for the quarter ended December 31, 2022, reached approximately $1 million, exceeding Vyleesi operating expenses.
- PL9643 for dry eye disease patient enrollment on track with topline data expected mid-calendar year 2023.
- First patient dosed in Phase 2 study of PL8177 for ulcerative colitis, with interim assessment expected in the first half of calendar year 2023 and topline data in the second half of calendar year 2023.
- Bremelanotide BREAKOUT study for diabetic kidney disease initiated enrollment in Q1 2023, with complete enrollment targeted for Q3 2023 and topline results expected in Q1 2024.
- The Company received $4,674,999 in January 2023 from the sale of NOLs and R&D credits.
Headline financials
Revenue & EPS history
Palatin Technologies · Revenue · Quarterly
$1.03M
Forward guidance
Palatin believes that existing cash and cash equivalents and receivables will be sufficient to fund currently anticipated operating expenses through calendar year 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-2.4%
Avg return
Earnings day
-0.6%
Avg return
5 days after
-2.5%
Avg return
30 days after
31%
20 / 64 earnings
Positive
+36.4%
Q3 2026
Best reaction
-27.1%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.2% | +29.2% | +18.2% | |
| Q1 2026 | +0.0% | +27.8% | +152.3% | |
| Q3 2026 | +36.4% | +9.1% | -9.1% | |
| Q3 2025 | +22.2% | +55.6% | +11.1% | |
| Q2 2025 | +7.1% | +4.0% | -20.2% | |
| Q1 2025 | -21.5% | -21.8% | -26.1% | |
| Q4 2024 | -8.3% | -1.1% | +39.3% | |
| Q3 2024 | -15.4% | -15.4% | -24.5% | |
| Q2 2024 | -27.1% | -21.7% | -62.8% | |
| Q1 2024 | -1.0% | -2.5% | +31.3% | |
| Q4 2023 | -8.5% | +19.7% | +13.3% | |
| Q3 2023 | -5.8% | -3.1% | -13.9% | |
| Q2 2023 | -8.8% | -2.2% | -18.0% | |
| Q1 2023 | -9.0% | -5.8% | -25.7% | |
| Q4 2022 | -19.5% | -27.7% | -43.6% | |
| Q3 2022 | -7.7% | -10.3% | -28.2% | |
| Q2 2022 | +5.0% | +0.0% | +2.5% | |
| Q1 2022 | -2.5% | -10.0% | +35.0% | |
| Q4 2021 | -6.4% | -8.5% | -12.8% | |
| Q3 2021 | +9.8% | +13.4% | +10.4% | |
| Q2 2021 | -19.5% | -23.9% | -33.6% | |
| Q1 2021 | +7.3% | +2.4% | +4.9% | |
| Q4 2020 | +0.0% | -4.2% | -20.8% | |
| Q3 2020 | -2.2% | -2.2% | +30.4% | |
| Q2 2020 | -14.1% | -18.3% | -39.4% | |
| Q1 2020 | -4.9% | -2.5% | -1.2% | |
| Q4 2019 | +7.1% | +3.0% | -16.2% | |
| Q3 2019 | +2.2% | +7.9% | -10.1% | |
| Q2 2019 | +2.7% | +6.8% | +36.5% | |
| Q1 2019 | -10.8% | -17.2% | -21.5% | |
| Q4 2018 | -3.8% | -2.9% | -14.3% | |
| Q3 2018 | -4.6% | -7.6% | -22.9% | |
| Q2 2018 | +5.6% | +7.8% | +6.7% | |
| Q1 2018 | +0.0% | +8.7% | +10.0% | |
| Q4 2017 | -6.1% | +0.0% | +15.2% | |
| Q3 2017 | -12.8% | -10.6% | -25.5% | |
| Q2 2017 | -6.8% | -11.4% | -22.7% | |
| Q1 2017 | -5.5% | -5.5% | +1.8% | |
| Q4 2016 | -1.8% | +16.1% | -3.6% | |
| Q3 2016 | -3.6% | — | — | |
| Q2 2016 | +2.0% | — | — | |
| Q1 2016 | -7.7% | — | — | |
| Q4 2015 | -8.5% | — | — | |
| Q3 2015 | +1.1% | — | — | |
| Q2 2015 | +23.0% | — | — | |
| Q1 2015 | +4.0% | — | — | |
| Q4 2014 | -5.0% | — | — | |
| Q3 2014 | -2.6% | — | — | |
| Q2 2014 | -7.0% | — | — | |
| Q1 2014 | +15.3% | — | — | |
| Q4 2013 | -7.0% | — | — | |
| Q3 2013 | +1.6% | — | — | |
| Q2 2013 | -5.9% | — | — | |
| Q1 2013 | +7.9% | — | — | |
| Q4 2012 | -6.3% | — | — | |
| Q4 2010 | -6.3% | — | — | |
| Q3 2011 | +5.0% | — | — | |
| Q3 2012 | +5.0% | — | — | |
| Q2 2012 | -5.9% | — | — | |
| Q2 2011 | -5.9% | — | — | |
| Q1 2012 | -3.8% | — | — | |
| Q1 2011 | -3.8% | — | — | |
| Q4 2011 | -3.8% | — | — | |
| Q3 2010 | -9.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro